Messa Emanuela, Cilloni Daniela, Saglio Giuseppe
Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Regione Gonzole 10, 10043 Orbassano (To), Italy.
Adv Hematol. 2010;2010:756289. doi: 10.1155/2010/756289. Epub 2010 Jun 20.
Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron chelators, which are easier to use and better accepted by the patients. The usefulness of iron chelation in MDS patients is still under debate, mainly because of the lack of solid prospective clinical trials that should take place in the future. This review aims to summarize what is currently known about the incidence and clinical consequences of iron overload in MDS patients and the state-of the-art of iron chelation therapy in this setting. We also give an overview of clinical guidelines for chelation in MDS published to date and some perspectives for the future.
骨髓增生异常综合征（MDS）是一种造血干细胞的异质性疾病，常表现为贫血和输血依赖。在低危患者中，输血依赖可能持续很长时间，导致铁过载。铁螯合疗法可能是这些患者的一种治疗选择，尤其是自口服铁螯合剂获批以来，其使用更方便且患者接受度更高。铁螯合在MDS患者中的有效性仍存在争议，主要是因为未来缺乏应开展的可靠前瞻性临床试验。本综述旨在总结目前已知的MDS患者铁过载的发生率和临床后果，以及这种情况下铁螯合疗法的最新进展。我们还概述了迄今为止发表的MDS螯合临床指南以及未来的一些展望。
